About

Intellipharm, LLC was founded by Kevin C. Johnson, an internationally renowned pharmaceutical scientist known for his research on modeling drug dissolution, absorption, and content uniformity. He is recognized for his development of the maximum absorbable dose calculation. After graduating from Kalamazoo College with a BA in chemistry, Kevin earned a Ph.D. in Pharmaceutics from The University of Michigan under the direction of Professor Gordon L. Amidon. Kevin joined Pfizer in 1986 and was awarded the Pfizer Central Research Achievement Award in 1998 “for improving the survival prospects of a number of emerging new drug candidates through personal initiative and scientific insight in defining the physical properties which increase oral absorption of the drug into the body.” He is a co-inventor on a ziprasidone patent for identifying a more soluble salt form of the drug.

Kevin has taught pharmacokinetics at the University of Connecticut, physical and analytical chemistry at Connecticut College, and general chemistry at Quinnipiac University. He holds a provisional certificate for teaching high school chemistry in the State of Connecticut and received the ETS Recognition of Excellence for scoring within the top 15% of all test takers who have ever taken the Praxis II Content Knowledge Assessment in Chemistry.

Kevin left Pfizer in 1999 to found Intellipharm, LLC. He has developed and written the code for all Intellipharm software products. Kevin also serves on the Editorial Advisory Board for the Journal of Pharmaceutical Sciences

Professional memberships: American Association of Pharmaceutical Scientists and American Chemical Society

Innovative Contributions to Pharmaceutical Research

Introduced first polydisperse drug powder computational method for dissolution under non-sink conditions
Proposed first combined dissolution, absorption, and metabolism computational method
Invented the maximum absorbable dose
Conceived of a time-dependent diffusion layer thickness
Developed physically realistic modeling of drug dissolution and absorption from the GI tract using one or more plugs of suspended drug particles experiencing dynamically changing permeability, solubility, and GI fluid volume depending on time-dependent plug position
Recommended first deterministic computational method for simulating content uniformity based on drug particle size distribution
Created mechanistic model for simulating precipitation

Publications

Kevin C. Johnson. Comparison of Methods for Predicting Dissolution and the Theoretical Implications of Particle-Size-Dependent Solubility. Journal Of Pharmaceutical Sciences 101 (2012) 681-689.

The above paper was selected by the editors to be featured on the journal’s website for 3 months under “Editors’ Picks” because the editors felt it contained “particularly original and significant” scientific findings.

Kevin C. Johnson. Dissolution and Absorption Modeling: Model Expansion to Simulate the Effects of Precipitation, Water Absorption, Longitudinally Changing Intestinal Permeability, and Controlled Release on Drug Absorption. Drug Development And Industrial Pharmacy 29 (2003) 833-842.

Ying Zhang and Kevin C. Johnson. Effect of drug particle size on content uniformity of low-dose solid dosage forms. International Journal of Pharmaceutics 154 (1997) 179-183.

Kevin C. Johnson and Archie C. Swindell. Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption. Pharmaceutical Research 13 (1996) 1795-1798.

Allan T. K. Lu, Mary E. Frisella, and Kevin C. Johnson. Dissolution Modeling: Factors Affecting the Dissolution Rates of Polysiperse Powders. Pharmaceutical Research 10 (1993) 1308-1314.

Rebecca J Hintz and Kevin C. Johnson. The effect of particle size distribution on dissolution rate and oral absorption. International Journal of Pharmaceutics 51 (1989) 9-17.

“The first true polydisperse model was developed by Hintz and Johnson…” quoted from Yanxing Wang, Bertil Abrahamsson, Lennart Lindfors, James G. Brasseur. Analysis of Diffusion-Controlled Dissolution from Polydisperse Collections of Drug Particles with an Assessed Mathematical Model. Journal Of Pharmaceutical Sciences 104 (2015) 2998-3017.